The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Brentuximab vedotin after autoSCT in pediatric patients with R/R Hodgkin lymphoma
Lisa Roth, MD, Weill Cornell Medicine, New York, NY, discusses a multicenter retrospective study of pediatric patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) who received brentuximab vedotin (BV) as maintenance therapy following autologous stem cell transplantation (autoSCT). Dr Roth shares that the treatment was well tolerated and safe, suggesting that this agent may be a promising option for pediatric patients. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
